High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study

Primary Care Respiratory Journal

Volumn 15, Issue 3, 2006, Pages 166-172

  Thomas, Mike ^a   Leather, David ^a   Price, David ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asthma; Inhaled corticosteroids; Pharmacosurveillance; Primary care

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; THEOPHYLLINE;

ADD ON THERAPY; ADULT; ARTICLE; ASTHMA; CONFIDENCE INTERVAL; CORTICOSTEROID THERAPY; DRUG MEGADOSE; DRUG UTILIZATION; GROUPS BY AGE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; SCHOOL CHILD; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33744510422     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.1016/j.pcrj.2006.02.009     Document Type: Article

References (37)

1. International consensus report on the diagnosis and treatment of asthma. Eur Respir J 5 (1992) 601-641
2. British Thoracic Society, Scottish Intercollegiate Guideline Network. British Guidelines on the Management of Asthma. Thorax 58 (2003) 1-94
3. Global Initiative for Asthma (GINA). Asthma management and prevention. NIH Publication No. 96-3659A. 1995. Bethesda, Maryland, NHLBI.
4. Barnes P.J., Pedersen S., and Busse W.W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 157 (1998) S1-S53
5. Barnes P.J. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 10 (1998) S427-S433
6. Lipworth B.J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 (1999) 941-944
7. Pedersen S., and O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52 suppl 39 (1997) 1-34
8. Suissa S., Ernst P., and Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 57 (2002) 880-884
9. Suissa S., Elphick H.E., Benayoun S., Baltzan M., and Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Eng J Med 343 (2000) 332-336
10. Szefler S., Martin R.J., King T.S., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109 (2002) 410-418
11. Adams N, Bestall J, Jones P. Beclomethasone at different doses for chronic asthma. The Cochrane Database of Systematic Reviews 1999, Issue 4. Art. No. CD002879, doi:10.1002/14651858.CD002879.
12. Price D., Hernandez D., Magyar P., et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled beclomethasone in adult patients with asthma. Thorax 58 (2003) 211-216
13. Bateman E.D., Boushey H., Busse W.W., Clark T.J.H., Pauwels R.A., and Pedersen S. Can Guideline-defined Asthma Control Be Achieved?. Am J Respir Crit Care Med 170 (2004) 836-844
14. Price D., Ryan D., Pearce L., and Bride F. The AIR study: asthma in real life. Asthma J 4 (1999) 74-78
15. Rabe K.F., Vermeire P.A., Soriano J.B., and Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 16 (2000) 802-807
16. Shrewsbury S., Pyke S., and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320 (2000) 1368-1373
17. Kips J.C., and Pauwels R.A. Long acting inhaled beta 2 agonist therapy in asthma. Am J Respir Crit Care Med 164 (2001) 923-932
18. Bjermer L., Bisgaard H., Bousquet J., et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327 (2003) 891-900
19. British Thoracic Society, The National Asthma Campaign, The Royal College of Physicians of London. The British guidelines on asthma management: 1995 review and position statement. Thorax 52 Suppl 1 (1996) S1-S21
20. Cumming R.G., Mitchell P., and Leeder S.R. Use of inhaled corticosteroids and the risk of cataracts. N Eng J Med 337 (1997) 8-14
21. Garbe E., LeLorier J., and Boivin J.F. Inhaled and nasal glucocorticoids and the risk of occular hypertension or open-angled glaucoma. JAMA 277 (1997) 722-727
22. Hubbard R.B., Smith C.J.P., Smeeth L., Harrison T.W., and Tattersfield A.E. Inhaled Corticosteroids and Hip Fracture. A Population-based Case-Control Study. Am J Respir Crit Care Med 166 (2002) 1563-1566
23. Todd G.R.D., Acerini C.L., Ross-Russell R., Zahra S., Warner J.T., and McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 87 (2002) 457-461
24. Drake A.J., Howells R.J., Shield J.P.H., et al. Lesson of the week: Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 324 (2002) 1081-1083
25. DIN-Link database, Compufile Ltd. www.compufile.co.uk. 2004.
26. Carey I.M., Cook D.G., de Wilde S., et al. Developing a large electronic primary care database (Doctors Independent Network) for research. Int J Med Inf 73 (2004) 443-453
27. Price D., and Duerden M. Chronic obstructive pulmonary disease - the lack of a national service framework should not allow us to ignore it. BMJ 326 (2003) 1046-1047
28. Thomas M., and Price D. The diagnosis and assessment of asthma in primary care. In: Scadding G., and O'Connor B. (Eds). Key Advances in the Clinical Management of Asthma (2004), The Royal Society of Medicine Press Ltd, London
29. Juniper E.F. The impact of patient compliance on effective asthma management. Curr Opin Pulm Med 9 (2003) S8-S10
30. Milgrom H., Bender B., Ackerson L., Bowry P., and Smith B. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 96 (1996) 1051-1057
31. Stoloff S.W., Stempel D.A., Mayer J., et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 113 (2004) 245-251
32. Suissa S., and Ernst P. Inhaled corticosteroids: Impact on asthma morbidity and mortality. J Allergy Clin Immunol 107 (2001) 937-944
33. Haahtela T., Jarvinnen M., Kava T., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Eng J Med 331 (1994) 700-705
34. Price D., Dutchman D., Mawson A., Bodalia B., Duggan S., and Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax 57 (2002) 791-798
35. Price D., Rouleau M.Y., Fletcher C.P., et al. Use of Montelukast in Tapering Inhaled Corticosteroid Therapy: An Open-Label. 48-Week Trial. Current Therapeutic Research 62 (2001) 11
36. Lofdhal C.G., Reiss T.F., Leff J., et al. Randomised placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 319 (1999) 87-90
37. Hawkins G., McMahon A.D., Twaddle S., Wood S.F., Ford I., and Thomson N.C. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 326 (2003) 1115